RGEN Overview

Repligen Corporation is a global life sciences company that develops and commercializes bioprocessing technologies and systems. Its franchises include filtration, chromatography, process analytics and proteins. Its filtration franchise includes product offering covering upstream and downstream technologies. Its filtration products include XCell Alternating Tangential Flow (ATF) Cell Retention Systems, Flat Sheet Cassettes, Hollow Fiber Consumables, Tangential Flow Filtration Systems and Fluid Management. Its chromatography franchise includes products used in downstream purification, development, manufacturing and quality control of biological drugs. Its chromatography franchise includes OPUS Pre-Packed Columns, KRM Chromatography Systems and other additional chromatography products. Its process analytics include Downstream process analytical technology (PAT) and Upstream PAT. Its Proteins include Protein A Affinity Ligands, AVIPure Resins for New Modalities and Growth Factors.

Wall Street analysts forecast RGEN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RGEN is189.00 USD with a low forecast of 165.00 USD and a high forecast of 207.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Repligen Corp revenue for the last quarter amounts to 197.91M USD, increased 18.12

Repligen Corp. EPS for the last quarter amounts to 0.23 USD, decreased -138.33

Repligen Corp (RGEN) has 2000 emplpoyees as of April 11 2026.

Today RGEN has the market capitalization of 6.77B USD.